Quanterix Corporation (QTRX) has a MoatMap StockRank of 15/100 based on Quality (36/100), Value (48/100), and Momentum (16/100) factor scores. The current signal is STRONG SELL. Life sciences tool provider with low quality metrics and no path to profitability, failing the Terry Smith and Warren Buffett criteria.
Quanterix Corporation develops and commercializes ultra-sensitive digital immunoassay platforms, Simoa technology, used for detecting and quantifying biomarkers at extremely low concentrations for early disease detection and research. Its proprietary Simoa technology offers significantly higher sensitivity than conventional immunoassays, providing a strong technological advantage in biomarker detection and creating high switching costs. Quanterix is a leader in ultra-sensitive biomarker detection, positioned at the forefront of precision medicine and early diagnostics.
| Price | $3.09 |
| Market Cap | $144M |
| P/E (Forward) | -2.79 |
| Price/Book | 0.63 |
| Return on Equity | -34.8% |
| Return on Invested Capital | -31.9% |
| Debt/Equity | 12.52 |
| Gross Margin | 45.3% |
| Operating Margin | -59.1% |
| Revenue Growth | 20.1% |
| Free Cash Flow | $-22M |
Quanterix Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).